Sinapsos Podcast | Oncology

E20   |  11 min   |   Latest   |  Publication Link

• Podcast based on: Michelon, I.; do Rêgo Castro, C.E.; Querino Belluco, A.P.; Dacoregio, M.I.; Priantti, J.; Witt, R.G.; Attia, S.; Vilbert, M.; Cavalcante, L. Multi-Targeted TKIs in Patients with Advanced Ewing Sarcoma: A Systematic Review and Single-Arm Meta-Analysis. Cancers 2026, 18, 465. https://doi.org/10.3390/cancers18030465
  Type: Systematic Review  |  Publication date: 30 January 2026
  
  
• Summary: Ewing sarcoma is a rare and aggressive cancer that often relapses after treatment. There is no clear standard therapy for patients whose disease progresses. Tyrosine kinase inhibitors have recently shown promising results. We reviewed and pooled data from published clinical trials and real-world studies to better evaluate the efficacy and safety of tyrosine kinase inhibitors in relapsed Ewing sarcoma patients. In our pooled analyses of 14 studies, we found an objective response rate of 23% and a disease control rate of 61.1%. Cabozantinib and regorafenib showed the most consistent benefits among drugs available in Western countries. These findings suggest the potential of tyrosine kinase inhibitors in the treatment of such a challenging population.
  
  
• Keywords: tyrosine kinase inhibitor; Ewing sarcoma; multiply refractory disease; TKI

License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.